While overstimulation of the CB1 receptor may lead to symptoms such as high blood pressure and abnormally high cholesterol levels, CBD is a CB1 antagonist, so it is not likely to cause such issues. Furthermore, the World Health Organization has recently issued a global report on CBD, claiming that it has a good safety profile and minimal adverse public health effects.
In your internet travels, you may also come across products called “terpsolates.” The manufacturers of these products infuse CBD Isolate with terpenes (but not cannabinoids like THC). These terpenes may enhance the effectiveness of CBD — or maybe they just make it smell good. This may be a good place to point out that not all CBD products are created equal. The industry is still largely unregulated, and the quality and quantity of CBD in a given product will vary wildly. Third-party testing definitely helps to monitor companies’ claims, but it’s still up to you as the consumer to do your homework on the best CBD products.
Transparency: Receptra Naturals’ website has a database where you can look up lab reports for their products. The first time we checked, we got some 404 errors for a couple of the lab reports, but these glitches seem to have been fixed since then. We were able to see third-party lab reports for all their tinctures (though, apparently not for their topicals).
Along the same lines a person who is anxious on a regular basis can throw their cortisol levels out of whack. A person with cortisol levels too high or too low end up with unpleasant symptoms. One of those symptoms can be increase in weight, which most of us try to avoid. CBD oils or supplements can help regulate a person’s cortisol levels so that they peak when they are supposed to and lower at appropriate times.
Various strains of "medical marijuana" are found to have a significant variation in the ratios of CBD-to-THC, and are known to contain other non-psychotropic cannabinoids. Any psychoactive marijuana, regardless of its CBD content, is derived from the flower (or bud) of the genus Cannabis. As defined by U.S. federal law, non-psychoactive hemp (also commonly-termed industrial hemp), regardless of its CBD content, is any part of the cannabis plant, whether growing or not, containing a ∆-9 tetrahydrocannabinol concentration of no more than 0.3% on a dry-weight basis. Certain standards are required for legal growing, cultivating, and producing the hemp plant. The Colorado Industrial Hemp Program registers growers of industrial hemp and samples crops to verify that the dry-weight THC concentration does not exceed 0.3%.
In the United States, the cannabidiol drug Epidiolex was approved by the Food and Drug Administration in 2018 for treatment of two epilepsy disorders. The side effects of long-term use of the drug include somnolence, decreased appetite, diarrhea, fatigue, malaise, weakness, and sleeping problems. As of July 2019 in the United States, CBD is a Schedule I controlled substance that is illegal for use in human foods, dietary supplements, other consumer products, or pet foods.